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Background: Infection risks among people who inject drugs
(PWID) are widely recognized, but few studies have focused on
image and performance enhancing drugs (IPEDs). Globally, concern
about IPED injection has increased and, in the United Kingdom,
IPED injectors have become the largest group using Needle and
Syringe Programmes. Blood-borne virus prevalence trends among
IPED injectors are explored.
Method: Data from 2 surveys of IPED injectors (2010–2011;
2012–2013) and the national bio-behavioral surveillance system for
PWID (1992–1997; 1998–2003; 2004–2009) were merged. Psycho-
active drug injectors and women were excluded. Logistic regression
analyses explored temporal changes.
Results: Between 1992 and 2009, median age increased from 25 to
29 years (N = 1296), years injecting from 2 to 4. There were 53 men
who had sex with men (MSM). Overall, 0.93% had HIV, 4.4% ever
had hepatitis B (HBV), and 3.9% hepatitis C (HCV, from 1998, N =
1083). In multivariable analyses, HIV increased in 2004–2009
[adjusted odds ratio (AOR) = 10 (95% conﬁdence interval (CI):
0.94 to 106) vs. 1992–2003], and remained elevated (AOR = 4.12,
95% CI: 0.31 to 54, 2012–2013); HBV also increased in 2004–2009
(AOR = 3.98, 95% CI: 1.59 to 9.97). HCV prevalence increase was
only borderline signiﬁcant (AOR = 2.47, 95% CI: 0.90 to 6.77,
2010–2011). HIV and HBV were associated with MSM and HCV
with sharing needles/syringes. Uptake of diagnostic testing for HIV
and HCV, and HBV vaccination increased (to 43%, 32% and 44%
respectively). Condom use was consistently poor; needle/syringe
sharing occurred.
Conclusion: Blood-borne virus prevalences among IPED injectors
have increased and for HIV, is now similar to that among
psychoactive drug injectors. Targeted interventions to reduce risks
are indicated.
Key Words: HIV, hepatitis B, hepatitis C, people who inject drugs,
behaviors, image and performance enhancing drugs
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INTRODUCTION
It is widely recognized that people who inject drugs
(PWID) are vulnerable to blood-borne viral (BBV) infections.
However, whilst BBVs have been extensively studied among
individuals who inject psychoactive drugs (such as opiates and
stimulants),1–3 few studies have focused on those who inject
image and performance enhancing drugs (IPEDs).4–7 A wide
range of illicit drugs can be injected with the aim of altering
body image and/or performance. These drugs range from
human growth hormone,8 a range of peptide hormones,9,10 the
most commonly injected IPED anabolic androgenic ste-
roids,3,11 to tanning drugs, such as “Melanotan II.”12
Globally, there is increasing concern about the extent
and public health consequences of IPED use,4,10,13 and
recently a number of studies have raised concerns about
infections, including HIV, among those who inject IPEDs.6,7
In particular, there has been concern that HIV and hepatitis B
virus (HBV) infections might have increased over time
among this group in the United Kingdom (UK).7 This has
occurred during a time when the number of people who inject
IPEDs in contact with needle and syringe programmes (NSPs)
has grown in the UK14 and Australia.15
Infection risks for BBVs among IPED injectors are,
for a number of reasons, likely to be different to those
among people injecting psychoactive drugs. Firstly, users’
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behaviors, and therefore risks of infection, can be impacted
by the effects of psychoactive drugs, with the use of these
leading to disinhibition and compulsive usage,16 although
there is increasing evidence to support some levels of
dependence amongst IPED users and for these drugs having
hedonic effects.17–19 Secondly, there are differences in
injecting practice, as IPEDs are injected only subcutane-
ously or intramuscularly and usually require much less
preparation than psychoactive drugs.3,7,14 Finally, IPEDs
are typically injected less frequently than psychoactive
drugs and their use can be cyclical.4,7,14 These differences
have been thought to place those who inject IPEDs at
a much lower risk of injection-related infections than those
who inject psychoactive drugs.4,14 However, studies suggest
that those using IPEDs may have greater sexual risks, as
they commonly report risky sexual behaviors4,7,20,21 and low
levels of condom use.7,20,22
In response to the increasing concerns about IPED use
and the possible increase in the prevalence of BBVs among
this population, data from a number of related sero-behavioral
surveys were used to examine temporal changes in the UK.
The aim of this study was to describe changes between 1992
and 2012 in (1) injecting risk; (2) sexual behaviors; and (3)
BBV prevalence among people injecting IPEDs.
METHODS
Data from cross-sectional sero-behavioral studies were
extracted and analyzed.
Surveys
In England and Wales, PWID have been recruited into
a voluntary unlinked-anonymous monitoring (UAM) survey
since 1990; methodological details of which have been
published previously.23,24 Brieﬂy, agencies providing services
to PWID (eg NSPs and addiction services) at sentinel
locations invite clients who have ever injected drugs to
participate. Sentinel sites are selected so as to reﬂect both the
geographic distribution and the range of services offered to
PWID. Those who consent to participate provide a biological
sample and self-complete a brief questionnaire. This survey
has multi-site ethics approval.
From 1990 to 2009, this survey had a single question-
naire focused on psychoactive drug use and collected oral
ﬂuid samples. During 2010, the biological sample was
changed to a dried blood spot (DBS) and the questionnaire
was reviewed. At the same time a UAM subsurvey focused
on IPED use was implemented, in response to the increased
concerns about risk in this group.14 The initial IPED
subsurvey during 2010–2011 collected oral ﬂuid samples
and used a modiﬁed questionnaire focused on IPED use.7
After this initial subsurvey, a routine biennial IPED sub-
survey was established using a similar questionnaire, but
collecting DBS samples. The ﬁrst wave of this routine survey
was undertaken during 2012–2013.25
The samples collected in the surveys were tested for
antibodies to HIV (anti-HIV), hepatitis B core antigen (anti-
HBc), and hepatitis C virus (anti-HCV), using previously
published methods by the same laboratory.7,26,27 Common
data items were extracted from the main UAM Survey and
the 2 subsurveys for male participants who reported
injecting only IPEDs during the preceding year. The main
UAM Survey had collected limited data on the drugs used
before 1992 and, because of the small number of IPED
users recruited into this survey annually, three 6-year time
periods (1992–1997, 1998–2003, 2004–2009) were used.
When combining data from 6 survey years into a single time
period only an individual’s ﬁrst participation during that
period was included (self-reported previous participations
were used to exclude repeats). Data analyzed were thus for
5 time periods; 3 from the main UAM Survey (1992–1997,
1998–2003, 2004–2009) plus the 2 IPED subsurveys
(2010–2011, 2012–2013).
Risk factors from the questionnaire data were analyzed
in categorical form for the most part, either based on yes/no
responses or predeﬁned categories in the questionnaire, or
groups in the case of continuous variables. The latter were
chosen to provide roughly equal size groups with a sufﬁcient
number in each. Factors of interest included the 5 time
periods, region [Southern and Eastern England; the Midlands
(England); Northern England; Wales], age (,25, 25–34, 35+
years), injecting duration (,2, 2–5, .5 years), UK born, ever
received a used needle/syringe, ever used a NSP, HBV
vaccination uptake, number of sexual partners (preceding
year; none, 1, 2–9, 10+), condom use (always, sometimes,
never), sexuality [men who have sex with men (MSM)], and
ever tested for HCV or HIV.
Statistical Methods
Changes in risk factors over time were assessed through
x2 tests with survey period for categorical variables; and for
some continuous variables, the association with time was
measured through Pearson’s correlation coefﬁcient. Risk
factors for BBV infection (HCV, HBV, and HIV) were
analyzed through logistic regression. Tests for HCV and HBV
had reduced sensitivity before the introduction of DBS; we
used a routine based on the expectation-maximization
algorithm to account for imperfect sensitivity and speciﬁcity28
implemented through the Stata command logitem. Although
we examined the relationship between past diagnostic testing
for HIV/HCV and HBV vaccination with infection status,
these variables were not included in multivariable analysis, as
there is not a causal relationship between previous testing and
infection status, nor for HBV vaccination and HCV/HIV
status; ie, these variables may show an association due to
higher uptake in high-risk individuals, but the test/vaccine
does not in itself change the risk of infection.
As there was a substantial proportion of missing data
for some variables, a multiple imputation approach was
employed in the primary analysis. Missing data can lead to
a loss of power, but more signiﬁcantly, informatively
missing data may lead to biased results in complete case
analyses, where only observations with no missing data are
analyzed.29 We used the approach of chained equations,
which produces multiple datasets of predicted values based
on the relationships between variables, and combines the
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results to account for uncertainty in predictions according to
Rubin’s rules30 (see Appendix A, Supplemental Digital
Content, http://links.lww.com/QAI/A747).
Due to the small number of observed infections, it was
desirable to ﬁnd a parsimonious model to describe the data.
As the number of potential covariates was not large,
a complete search of all possible models was undertaken
for each infection, and the Akaike31 information criteria used
for comparisons. Time-period was included in all models, as
trends over time are of principal interest.
RESULTS
Descriptive Statistics
In total, 1296 participations were included in the
analyses, with 611 (47%) from 2010 onwards and the fewest
during 2004–2009 (129, 10%). Figure 1 and Table 1 show
distributions of participant characteristics over time. The age
and injecting duration of those sampled increased (P , 0.001
for both), with a median injecting duration of 2 years (IQR
0–4) in 1992–1997 and 4 years (IQR 1–10) in 2012–2013;
and a median age of 25 years (IQR 22–29) in 1992–1997 and
29 years (IQR 23–35) in 2012–2013. Condom use showed no
signiﬁcant change over time (P = 0.355); overall only 20.5%
reporting always using a condom, with 39.5% sometimes
doing so, and 40% never. Signiﬁcant differences in reported
number of sexual partners during the preceding year was
observed over time (P = 0.012) although this did not show
any overall trend. Overall, 6.8% reported no partners, 42% 1,
42% 2–9 and 9.9% 10 or more.
Other behavioral and demographic variables showed
some changes over time; ever used NSP varied between 78%
and 90%. Reporting ever receiving used needles/syringes
increased from 13% in 1992–1997 to 34.5% in 1998–2003
and 40% in 2004–2009 before dropping to less than 6% from
2010; this drop might be related to the move to the IPED
focused questionnaire in 2010 even though questions were
similar. Vaccination for HBV and testing for HCV and HIV
increased between 1998 and 2003 and 2004 and 2009, and
stayed roughly stable thereafter. The proportion born in the
UK and MSM have both remained stable over time, with 712/
746 (95%) UK-born overall (data collected from 2004 only)
and 53 (4.1%) MSM.
In total 42/1083 (3.9%) participations tested positive for
anti-HCV; 57/1296 (4.4%) for anti-HBc; and 12/1296
(0.93%) for anti-HIV. Figure 2 shows prevalence of these 3
infections over time. Prevalence rose sharply for all 3
infections in the 2004–2009 period, but fell again in 2010–
2011 and 2012–2013.
Patterns of Missing Data
Injecting duration had the largest amount of missing
data (mainly due to age ﬁrst injected being missing); most of
the other variables contained relatively small amounts (,5%)
of missing data and a number of data items (eg UK born)
were not collected in earlier survey years and therefore were
missing for these (see Appendix A, Supplemental Digital
Content, http://links.lww.com/QAI/A747). Crucially, those
missing injecting duration were more likely to have positive
test results for HCV and HIV (P = 0.077 and 0.153
respectively); and this difference increased over time, with
those missing injecting duration having prevalences 2–3
times as high in 2012–2013 for all 3 infections. This indicates
a risk of bias in complete case analysis of trends.
Model Selection
The model selection phase, based on the imputed
data, did not yield a clear choice in model structure in terms
of a single best-scoring model, although some variables
could be excluded with relative certainty (where variables
did not appear in any of the best-scoring models). For HCV
and HBV, number of partners and condom use did not
feature in any of the best-scoring models, and being born in
the UK featured infrequently; these variables were there-
fore omitted and all other variables were retained. This
resulted in some “redundant” variables, but allowed a more
direct comparison between the results for HCV and HBV.
For HIV, results were even more uncertain, with MSM
appearing in all best scoring models but little certainty as to
FIGURE 1. Distribution of reported
injecting duration and age (at time of
survey) over time, men injecting
IPEDs, England and Wales: 1992–
2013. Box and whisker plots with
medians, 25th and 75th percentiles
and whisker defined as 1.5 times the
interquartile range.
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which other variables should be included; the only ﬁrm
conclusion was that very few variables could be included
without over-ﬁtting to the data. We selected MSM,
age, ever received used needles/syringes and condom
use for the ﬁnal model. Detailed tables of the model
selection results and Akaike information criteria scores
are shown in Appendix B (see Supplemental Digital
Content, http://links.lww.com/QAI/A747).
Logistic Regression Results
Table 2 shows results from multivariable models for
HCV, HBV and HIV, based on data from the multiple
imputation (MI) analysis. In most cases, the univariable
complete case, univariable MI and MI multivariable analyses
give fairly similar results; we therefore focus on the multivari-
able MI results, but highlight differences between the
analyses where they occur. Full details of the different models
are given in Appendix C (see Supplemental Digital Content,
http://links.lww.com/QAI/A747).
Differences between regions followed a similar pat-
tern for all 3 infections, with Southern and Eastern England
having the highest prevalence and Wales the lowest. HCV
prevalence increased over time, although was only border-
line signiﬁcant in 2010–2011 with an odds ratio (OR) of
2.47 (95% CI: 0.90 to 6.77) vs. 1999–2003. The pattern is
rather different to the unadjusted ORs, which had an
increase in 2004–2009 then decreasing subsequently; the
difference in the multivariable results is largely due to
adjusting for ever receiving used needles/syringes; numbers
reporting ever receiving needles/syringes dropped signiﬁ-
cantly in the last 2 periods, but prevalence of HCV did not
fall correspondingly.
There are some similarities in the temporal pattern for
HBV, but prevalence increased more markedly in 2004–2009
with an OR of 3.98 (95% CI: 1.59 to 9.97), then decreasing
over the next 2 periods. The pattern for HIV was similar, but
with an extremely high, albeit uncertain increase in 2004–
2009 with an OR of 10.01 (95% CI: 0.94 to 106.3) and falling
in the subsequent 2 periods. The ORs were attenuated in the
FIGURE 2. Observed prevalence and 95% confidence inter-
vals of anti-HCV, anti-HBc, and anti-HIV prevalence over time,
accounting for imperfect test sensitivity and specificity, men
injecting IPEDs, England and Wales: 1992–2013. No data are
available for anti-HCV before 1998 when testing was first
introduced into the survey.
TABLE 1. Characteristics of Participations by Men Injecting IPEDs Over Time, England and Wales: 1992–2013
Men injecting IPEDs Participating in
the Main UAM Survey of PWID
UAM Subsurveys of People
Injecting IPEDs
P Value1992–1997 1998–2003 2004–2009 2010–2011 2012–2013
N participations 213 343 129 383 228
Injecting duration 2 (0–4) 2 (1–5) 3 (1–8) 3 (1–8) 4 (1–10) ,0.001
Age 25 (22–29) 28 (23–32) 29 (24–33) 28 (23–35) 29 (23–35) ,0.001
Never used condom 38% 41% 34% 42% 41% 0.355*
More than 1 sexual partner 47% 56% 49% 51% 52% 0.012*
Area
London, Southern and Eastern England 22% 14% 19% 33% 14%
Midlands (England) 16% 22% 10% 16% 33%
Northern England 40% 51% 45% 36% 20%
Wales 22% 13% 26% 16% 32% ,0.001†
Ever used NSP 81% 90% 78% 90% 0.001
Ever received used needle/syringe 13% 35% 40% 5.8% 4.9% ,0.001
HBV vaccination ‡ 21% 46% 34% 44% ,0.001
Tested for HIV 15% 18% 42% 36% 43% ,0.001
Tested for HCV ‡ 7.9% 31% 29% 32% ,0.001
UK-born ‡ 100% 96% 95% 96% 0.81
MSM 3.3% 3.5% 4.7% 3.4% 6.6% 0.305
P values indicate signiﬁcance of changes over time.
*P values for condom use and number of partners are based on full categorical variables rather than the dichotomized versions presented here.
†P value for area based on joint distribution of all areas.
‡Data not collected during this time period.
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multivariable analyses compared with univariable results, but
all results exhibit substantial uncertainty.
For each of the 3 infections, prevalence was similar
for those aged 25–34 vs. ,25, but signiﬁcantly higher in the
35+ age group in univariable analysis; however, there was
no association after adjusting for injecting duration, which
is highly correlated with age. Injecting duration was
signiﬁcantly associated with HCV status, with ORs of
6.23 (95% CI: 1.27 to 30.42) and 8.53 (95% CI: 1.66 to
43.78) for 2–5 years and 5+ vs. ,2 years respectively.
Interestingly, despite the high risk of bias identiﬁed due to
missing data, results for the univariable complete case
analysis were very similar. The effect of injecting duration
on HBV followed a similar pattern, but weaker; and results
for HIV were similar to HBV, but highly uncertain. The
different patterns in injecting risk for the 3 infections were
further borne out by results for ever receiving used needles/
syringes, which had a strong effect for HCV with an OR of
5.57 (95% CI: 2.32 to 13.37) and positive, but nonsignif-
icant effect for HBV and HIV. Ever using a NSP was found
to be protective for HCV (P = 0.066) but nonsigniﬁcant
for HBV.
Sexuality was found to be an important risk factor for
HBV and HIV, with MSMs having a far higher prevalence,
with ORs of 6.58 (95% CI: 2.65 to 16.34) for HBV and 17.76
(95% CI: 4.20 to 75.13) for HIV, and nonsigniﬁcant for HCV.
Apart from survey period, MSM was the only variable to
remain signiﬁcant in the multivariable analysis of HIV.
Reported number of partners and condom use had little
association with any infections, even in univariable analyses.
We attempted to examine whether the effects of other variables
differed according to sexuality, ie through interactions with
MSM, but data were too sparse to do so.
Previous diagnostic testing for HCV and HIV showed
signiﬁcant positive associations with all 3 infections; as
mentioned previously this must be interpreted as a difference
in underlying risk in those seeking tests and not a causal
factor; ie testing does not cause an increased risk of infection.
HBV vaccination showed little association with HCV and
HBV status, but HIV prevalence was somewhat higher in
TABLE 2. Multivariable Logistic Regression Results for Anti-HCV, Anti-HBc, and Anti-HIV, Based on Multiple Imputation Model
Data, Men Injecting IPEDs, England and Wales: 1992–2013
Number
Observations
Anti-HCV Anti-HBC Anti-HIV
OR 95% CI P value OR 95% CI P value OR 95% CI P value
Area
London, Southern
and Eastern
England
278 1 (ref) 1 (ref)
Midlands
(England)
259 0.58 0.22 to 1.50 0.258 0.37 0.15 to 0.92 0.032
Northern England 501 0.61 0.27 to 1.36 0.224 0.40 0.20 to 0.80 0.009
Wales 258 0.19 0.05 to 0.73 0.015 0.20 0.07 to 0.55 0.002
Year
1992–1997 213 NA 0.75 0.22 to 2.57 0.648 1 (ref)*
1998–2003 343 1 (ref) 1 (ref)
2004–2009 129 1.54 0.51 to 4.59 0.441 3.98 1.59 to 9.97 0.003 10.01 0.94 to 106.33 0.056
2010–2011 383 2.47 0.90 to 6.77 0.080 1.55 0.66 to 3.66 0.317 6.46 0.65 to 64.57 0.112
2012–2013 228 2.07 0.64 to 6.71 0.225 0.47 0.13 to 1.66 0.243 4.12 0.31 to 54.13 0.281
Age, yrs
,25 425 1 (ref) 1 (ref) 1 (ref)
25–34 588 0.48 0.16 to 1.44 0.191 0.56 0.26 to 1.23 0.151 0.57 0.07 to 4.42 0.590
35+ 250 1.55 0.52 to 4.60 0.426 0.64 0.25 to 1.67 0.364 2.70 0.43 to 16.87 0.288
Injecting duration, yrs
,2 379 1 (ref) 1 (ref)
2–5 391 6.23 1.27 to 30.42 0.024 2.12 0.86 to 5.23 0.102
.5 297 8.53 1.66 to 43.78 0.010 2.68 0.99 to 7.27 0.053
Ever used NSP 718/862† 0.43 0.18 to 1.06 0.066 0.70 0.32 to 1.56 0.389
Ever received used
needle/syringe
227/1272† 5.57 2.32 to 13.37 ,0.001 1.75 0.82 to 3.73 0.147 3.39 0.71 to 16.28 0.127
MSM 53/1296† 1.90 0.58 to 6.23 0.287 6.58 2.65 to 16.34 ,0.001 17.76 4.20 to 75.13 ,0.001
Condom use
Always 253 1 (ref)
Sometimes 487 2.11 0.45 to 9.93 0.343
Never 493 0.38 0.03 to 4.15 0.425
*1992–1997 and 1998–2003 periods combined for HIV.
†Number of “yes” responses/observed response.
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univariable analyses. Finally, being UK born showed no
signiﬁcant associations, although numbers of non-UK born
are low, and the effect could not be estimated for HIV, as
there were no infections in this group.
DISCUSSION
Our ﬁndings conﬁrm that BBV infections are a problem
among people who inject IPEDs, though in part this reﬂects an
overlap with the MSM population. Even so, the prevalence of
HIV is similar to that among those injecting psychoactive
drugs in the UK.32 Though the prevalences of HBV and HCV
are lower than among those who inject psychoactive drugs,33,34
they are most probably higher than the levels in the general
population.33–35 Worryingly, even though the prevalence of
these 3 infections might have peaked in the second half of the
2000’s, they are currently still higher than during the 1990’s.
This study has a number of limitations. Firstly, the
representativeness of those recruited is impossible to measure,
as the marginalization, comparative rarity and illicit nature of
injecting drug use all impeded the construction of a sampling
frame. Although the survey used an established methodology
for recruiting PWID23,24; its robustness for people who inject
IPEDs is not known and cannot be assessed as information on
the nature and size of this group is limited.4,14 Secondly, the
ﬁndings here rely on self-reports; although the reliability of
these has not been assessed among IPED users, they have
been found to be reliable for people injecting psychoactive
drugs.36,37 The reliability of the sexuality data is a particular
concern as this was based on the response to a single question
about male sexual partners and therefore the extent of sex
with men may be underreported. Responses were occasion-
ally incomplete leading to missing data, particularly in
relation to age at ﬁrst injection. This problem was partly
overcome by the use of MI methods, although it is unclear to
what degree bias due to systematic missingness may persist;
there is no guarantee that the observed relationships between
variables in the complete data hold for those with missing data.
In general, MI and complete case analyses were in close
agreement; although this does not validate the MI approach, it
is reassuring that radical differences are not observed. Thirdly,
though the infection data were based on the testing of
biological samples, analysis was limited by the small numbers,
particularly for HIV. Finally, though the data are drawn from
the same programme of sero-behavioral surveys there is some
methodological variation over time; in particular the ﬁrst three
time points drew on a survey of PWID focused on psychoac-
tive drug use, whilst the 2 more recent time periods relate to
purposive surveys of IPED injectors. There may be differences
between the risk proﬁles of those captured in these 2 survey
variants, and considering the higher level of sharing, those
captured in the general PWID survey might have been a higher
risk group. Considering these limitations, caution is needed
when attempting to generalize our ﬁndings.
The 3 infections examined here share a common route
of transmission through injecting, but HBV and HIV are also
readily transmitted sexually. The sexual transmission of HCV
is rare,38 though this may be more common among some
groups of MSM, particularly when infected with HIV. The
results here, although uncertain, reﬂect this risk pattern: the
associations of injecting duration and receiving used needles/
syringes with HCV infection are stronger than those for HBV
and HIV, with the latter presumably being diluted by the
sexual transmission route, which might be assumed relatively
high in this population.7,14 This also appears to be conﬁrmed
by the very strong association of HBV and HIV infection with
MSM, which was not observed for HCV. If transmission
routes for the 3 infections were identical, one would expect
the temporal trends to be similar; indeed, there are some
differences, with a large “spike” in prevalence anti-HBc in
2004–2009 followed by a tailing off, which is similar to the
pattern of HIV, compared with a relatively ﬂat proﬁle over
time for HCV. The differences in transmission routes are also
borne out by the correlation between infections; HIV has no
evidence of an association with HCV (although data are
sparse) with an OR of 2.09 (0.27–16.40) but a strong
association with HBV: OR = 14.27 (4.68–46.72). HCV and
HBV have an OR of 7.91 (3.75–16.68); in general, all 3
infections are likely to be correlated due to the shared route of
injecting, but for HIV and HBV this is expected to be stronger
due to these also being sexually transmitted. These theories
would be better conﬁrmed by modeling all 3 infections jointly
to separate out the effect of sexual transmission, but due to the
paucity of data this was not possible to test formally.
The extent of these infections and the indication of an
increase in prevalence over time for HIV and HCV are
a concern. Particularly, as our data indicate that the uptake of
diagnostic testing for HIV and HCV among men injecting
IPEDs (42.2% and 32.7%, respectively, in 2012–2013) is
much lower than among those injecting psychoactive
drugs,33,39 and HBV vaccine uptake (44.5% in 2012–2013)
is poor. Considering the injecting and sexual risks in this
population, there is a substantial potential for extensive
unrecognized spread of BBVs among those injecting IPEDs.
Though the relative roles of injecting and sexual risks in the
transmission of HIV and HBV need further examination,
these ﬁndings indicate that those providing services to PWID
need be alert to the infection risks among those who inject
IPEDs. In particular, they need to be aware that injecting
practices associated with IPED use differ from those for
psychoactive drugs4,7,14 and of the potentially greater sexual
risks.4,7,14 Services working with PWID need to ensure that
those injecting IPEDs have access to appropriate injecting
equipment, targeted harm reduction advice, testing for BBVs,
hepatitis B vaccinations, sexual health services, and condoms.
This study reports on the largest sample so far of people
who use IPEDs analyzed in relation to BBV infections and is
the ﬁrst to examine risk over time, however, the results need
to be interpreted with caution. Though further work is needed,
the ﬁndings indicate that both sexual and injection risks lead
to BBV transmission among those injecting IPEDs. The
extent of IPED use, the characteristics of the users and the
drug use proﬁles of IPED injectors attending NSPs in the UK
have all changed over time.14,40 However, the role of these
factors in the changing BBV prevalence requires further
investigation. These results also demonstrate the need for
targeted interventions to address sexual health and drug use
risks among those injecting IPEDs.
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